Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 28 filings·Updated 12 Aug 2026
Showing 10 of 28 filings.
12 Aug 20262 filings
OthersBusiness Responsibility and Sustainability Reporting (BRSR)

P&G Health India BRSR FY2025-26 highlights workforce, energy, emissions, and governance metrics

Overview

  • BRSR filed for FY2025-26 by Procter & Gamble Health Ltd as part of the annual report.
  • Report covers energy, water, emissions, waste, employees, and stakeholder grievances.
  • Scope and consolidation status not explicitly detailed in the provided extract.

Key ESG Risks & Opportunities

  • No explicit material ESG risks or opportunities stated in the excerpt.
  • Ethics training conducted: five programs with 100% coverage.
  • Disciplinary actions for bribery/corruption: two individuals.

Governance & Policy Highlights

  • Disciplinary actions for bribery/corruption: two individuals.
  • PF and gratuity coverage reported at 100% for employees and workers.
  • Board women representation: 2 of 7; KMP women: 1 of 3.
  • Safety incidents recorded: one in 2025-26 and one in 2024-25.

Social Responsibility & Workforce

  • Total employees (excluding workers): 221; 73% male, 27% female.
  • Total workers: 1,279; 87% male, 13% female.
  • Board has two women; KMP has one woman.
  • Gross wages paid to females: 15% of total in FY25-26; 22% in FY24-25.
  • 100% health insurance and gratuity coverage for employees and workers.
  • Training focus: health, safety, and skill upgradation; 100% training coverage.
  • Parental leave: 100% return-to-work and retention rates.

Environmental Performance

  • Total energy: 46,995 GJ; renewable 29,435 GJ; non-renewable 17,560 GJ.
  • GHG emissions (Scope 1+2): 190 MT CO2e.
  • Water: withdrawal 55,888 kL; consumption 26,764 kL; discharge 29,124 kL.
  • Total waste generated: 275.41 MT in FY25-26.
  • Revenue intensity: 0.05 MT CO2e per lakh; 0.01 in prior year.

Stakeholder Engagement & Complaints

  • Stakeholder complaints FY2025-26: 40; pending resolution: 1.
  • FY2024-25 complaints: 33; pending resolution: 1.
  • Consumer complaints: FY2025-26 = 70; FY2024-25 = 71.

Other Notable Metrics

  • Inputs from sustainable sources: 13.00% FY2025-26 vs 20.30% FY2024-25.
  • Share of inputs from suppliers: 89.09% FY2025-26 vs 79.70% FY2024-25.
  • Job creation in smaller towns: wages as % of total cost - 13%, 28%, 59%.
Filed 16:48View Source
AGM/EGMAGM

P&G Health to hold 59th AGM via VC on Sept 3, 2026; final dividend proposed and governance changes

AGM details

  • Date/time/mode: Sept 3, 2026 at 2:30 PM, via VC/OAVM.
  • Deemed venue: registered office; record date: Aug 27, 2026.
  • Register/Book closures: Aug 28–Sep 3, 2026.

Resolutions proposed

  • Ordinary: adoption of Audited Balance Sheet and P&L.
  • Ordinary: interim dividend paid; final dividend proposed.
  • Ordinary: re-appointment of Aalok Agrawal as Director (rotation).
  • Ordinary: ratification of Cost Auditor remuneration for FY 2026-27.
  • Special: re-appointment of S. Madhavan as Non-Executive Independent Director for five years.

Voting results

  • Voting outcomes not disclosed in this filing chunk.

Dividend

  • Interim dividend of ₹160 per share paid; final dividend ₹45 per share proposed; total ₹205 per share.

Director changes

  • Lokesh Chandak resigned as Executive Director & CFO, effective 30-Sep-2025.
  • Shashank Srowthy appointed Executive Director & CFO, effective 1-Oct-2025.
  • Aalok Agrawal to be reappointed; retires by rotation.
  • S. Madhavan re-appointed as Non-Executive Independent Director for five years from 15-Nov-2026.

Auditor appointments

  • Statutory auditors: Haribhakti & Co. LLP; tenure to 60th AGM; remuneration ₹43 lakhs.
  • Secretarial auditors: Dholakia & Associates LLP; term Apr 2025–Mar 2030.
  • Cost auditors: Joshi Apte & Associates; remuneration ₹5 lakhs for 2026-27.

Material related party transactions

  • Dividend paid to ultimate holding company: ₹17,632 lakhs.
  • Royalty paid to ultimate holding company: ₹2,707 lakhs.
  • Service cross-charges to fellow subsidiaries: ₹2,239 lakhs.
  • Sale of products to fellow affiliates: ₹6,286 lakhs.
  • Purchase of goods from PG group entities: ₹1,369 lakhs.

Other material approvals

  • CSR policy adoption and governance policies including board diversity and risk management.
  • Nomination and Remuneration Policy and board evaluation process.
Filed 16:38View Source
10 Aug 20261 filing
Corp. ActionRecord Date

Procter & Gamble Health sets record date for AGM and potential final dividend

Key dates

  • Record date for AGM and final dividend set as August 27, 2026.
  • AGM scheduled on September 3, 2026.
  • Final dividend payable only if approved by members at the AGM.
Filed 18:53View Source
15 Jul 20261 filing
Company UpdateGeneral

P&G Health updates AGM date to Sept 3, 2026 and record date to Aug 27, 2026

AGM date and record date update

  • Revised date for the 59th AGM: September 3, 2026.
  • Record date for AGM and final dividend: August 27, 2026.
  • Final dividend, if approved, to be paid by September 27, 2026.
Filed 18:25View Source
3 Jul 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

PG Health dematerialisation details for quarter ended June 30, 2026 furnished to exchanges

Dematerialisation processing confirmation

  • KFin confirms dematerialised securities for quarter ended 30 June 2026 were furnished to stock exchanges on time
  • NSDL and CDSL confirmations state details were furnished to all exchanges
Filed 18:03View Source
4 Jun 20261 filing
Company UpdateAnalyst / Investor Meet

We wish to inform you that the management of the Company will be hosting a virtual connect with analysts/ institutional investors on June 18th at 2.30 pm IST. Institutional investors/Analysts ....

Filed 14:25View Source
6 Apr 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Dear Sir/Madam, Please find attached disclosure under regulation 74(5) of the SEBI (DP) Regulations, for the quarter ended March 31, 2026.

Filed 10:49View Source
27 Mar 20262 filings
Board Meeting

Procter & Gamble Health Ltd - 500126 - Board Meeting Intimation for Intimation Of Board Meeting

Meeting Details

  • Board meeting scheduled for May 26, 2026

Key Agenda Items

  • Approval of audited financial statements for FY ended March 31, 2026
  • Consideration of final dividend recommendation
Filed 13:57View Source
Insider Trading / SASTClosure of Trading Window

Intimation for closure of trading window

Filed 13:55View Source
6 Feb 20261 filing
Company UpdateGeneral

Dear Sir, Please find attached communication in respect of deduction of TDS on the amount of dividend income from declaration of interim dividend for the Financial year 2025-26.

Filed 17:45View Source
Showing 10 of 28 filings